Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer
Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancerAssessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer, Published online: 17 April 2019; doi:10.1038/s41391-019-0147-0Assessing the relationship between statin use and oncologic outcomes among men electing active surveillance for localized prostate cancer
Telephone intervention linked to rise in men ’s vegetable consumption but not to drop in risk of progression Related items fromOnMedica Less regular PSA screening puts men at risk NICE guidance delays hinder good diabetes care Population weight control best for cutting diabetes prevalence Starting statins not beneficial in many older adults NHS must hold CCGs accountable for poor diabetes care
ConclusionMetformin and statins were not associated with BFFS or DFFS improvement in our analysis. However, the small number of patients treated with these drugs limits the reliability of the results and prospective studies are needed.
MONDAY, Dec. 2, 2019 -- Current statin use is inversely associated with the risk for lethal prostate cancer, according to a study published online Nov. 21 in Clinical Cancer Research. Emma H. Allott, Ph.D., from Queen's University Belfast in the...
Researchers at Queen's University in Belfast suggested the cholesterol-lowering drugs could reduce swelling the prostate and avoid deadly cancer, but overall rates of cancer were unchanged.
CONCLUSIONS: Molecular tumor classification identified PTEN and inflammation/immune activation as potential mechanisms linking statins with lower lethal prostate cancer risk. These findings support a potential causal association and could inform selection of relevant biomarkers for statin clinical trials. PMID: 31754047 [PubMed - as supplied by publisher]
The association between statins therapy and prostate cancer is extensively studied [1,2]. Recently, one cohort study conducted by Van Rompay et al. published in European Journal of Cancer demonstrated that statins use was associated with a lower mortality of prostate cancer than non-use (hazard ratio 0.73, 95% confidence interval 0.66–0.81) . This result was compatible with another cohort study in Finland showing that statins use aft er prostate cancer diagnosis was associated with 20% reduced mortality of prostate cancer (hazard ratio 0.80, 95% confidence interval 0.65–0.98) .
We found that statin use might be associated with reduced risk of both low ‐ and high‐grade prostate cancer, but the reduced risk was observed only when statins had been used for a relatively longer duration or higher dose. Also, the statin‐related risk reduction was higher for prostate cancer of a higher Gleason score, and lipophilic statins might be more protective than hydrophilic statins against prostate cancer. AbstractBackgroundConflicting evidence suggests that statins act chemopreventively against prostate cancer (PCa). Whether the association of statin use with PCa risk is Gleason score ‐dependent, time‐...
ConclusionsOur findings show that oncologists and physicians have a rational approach to deprescription in patients suffering from cancer with short-term (pancreatic and lung cancer) respectively long-term (breast and prostate cancer) survival rates. However, several patients were continuing potential inappropriate medications in the terminal stage of cancer.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
ConclusionsThese analyses suggest the pharmacokinetic profile of darolutamide is not affected by a number of commonly administered drugs in patients with nmCRPC. Although pharmacokinetic data have indicated that darolutamide has the potential to interact with rosuvastatin, used to assess DDI in these studies, this finding did not seem to translate into increased AEs due to statin use in the ARAMIS trial.Clinicaltrials.gov identifier: NCT02200614.
onomura Prostate cancer is the most common type of cancer and the leading cause of cancer deaths among men in many countries. Preventing progression is a major concern for prostate cancer patients on active surveillance, patients with recurrence after radical therapies, and patients who acquired resistance to systemic therapies. Inflammation, which is induced by various factors such as infection, microbiome, obesity, and a high-fat diet, is the major etiology in the development of prostate cancer. Inflammatory cells play important roles in tumor progression. Various immune cells including tumor-associated neutrophils, ...